Proof of concept: A bioinformatic and serological screening method for identifying new peptide antigens for Chlamydia trachomatis related sequelae in women by Stansfield, Scott et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Stansfield, Scott H., Patel, Pooja, Debattista, Joseph , Armitage, Charles
W., Cunningham, Kelly, Timms, Peter, Allan, John , Mittal, Aruna , & Hus-
ton, Wilhelmina M. (2013) Proof of concept : A bioinformatic and serolog-
ical screening method for identifying new peptide antigens for Chlamydia
trachomatis related sequelae in women. Results in Immunology, 3, pp.
33-39.
This file was downloaded from: http://eprints.qut.edu.au/63957/
c© Copyright 2013 The Authors. Published by Elsevier B.V.
This is an open-access article distributed under the terms of the Cre-
ative Commons Attribution-NonCommercial-No Derivative Works License,
which permits noncommercial use, distribution, and reproduction in any
medium, provided the original author and source are credited.
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1016/j.rinim.2013.05.001
Proof of Concept: A bioinformatic and serological screening method for 
identifying new peptide antigens for Chlamydia trachomatis related sequelae in 
women 
Scott H. Stansfield1, Pooja Patel1, Joseph Debattista2, Charles W. Armitage1, Kelly 
Cunningham1, Peter Timms1, John Allan 3, Aruna Mittal4, Wilhelmina M. Huston 1* 
 
1. Institute of Health and Biomedical Innovation, Queensland University of Technology, 
Kelvin Grove, QLD 4059,  AUSTRALIA 
2. Metro North and Sunshine Health Service Districts, Sexual Health and HIV Service, 
Queensland Health, 270 Roma St, Brisbane, QLD 4000 
3. The Wesley Research Institute and The Wesley Reproductive Medicine and 
Gynaecological Surgery Unit, The Wesley Medical Centre, 40 Chasley Street, 
Auchenflower, QLD 4066, AUSTRALIA 
4. Institute of Pathology- ICMR, Safdarjung Hospital Campus, Post Box no. 4909, New 
Delhi 110 029, INDIA 
* Corresponding author: Dr Wilhelmina (Willa) May Huston, email: w.huston@qut.edu.au, 
phone +61 7 31386258 , fax +61 731386030 
 
Abstract 
This study aimed to identify new peptide antigens from Chlamydia (C.) trachomatis in a proof of 
concept approach which could be used to develop an epitope-based serological diagnostic for C. 
trachomatis related infertility in women. A bioinformatics analysis was conducted examining 
several immunodominant proteins from C. trachomatis to identify predicted immunoglobulin 
epitopes unique to C. trachomatis.  A peptide array of these epitopes was screened against 
participant sera. The participants (all female) were categorized into the following cohorts based 
on their infection and gynecological history; acute (single treated infection with C. trachomatis), 
multiple (more than one C. trachomatis infection, all treated), sequelae (PID or tubal infertility 
with a history of C. trachomatis infection), and infertile (no history of C. trachomatis infection 
and no detected tubal damage). The bioinformatics strategy identified several promising 
epitopes. Participants who reacted positively in the peptide 11 ELISA were found to have an 
increased likelihood of being in the sequelae cohort compared to the infertile cohort with an odds 
ratio of 16.3 (95% c.i. 1.65 – 160), with 95% specificity and 46% sensitivity (0.19-0.74). The 
peptide 11 ELISA has the potential to be further developed as a screening tool for use during the 
early IVF work up and provides proof of concept that there may be further peptide antigens 
which could be identified using bioinformatics and screening approaches.     
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1. Introduction 
 
Chlamydia (C.) trachomatis is the most prevalent sexually transmitted bacterial infection 
worldwide, with 1,307,893 infections reported in the USA in 2010  [1]. The infection is 
frequently asymptomatic and thus actual case numbers are higher than those notified [2-3]. The 
major burden of Chlamydia infections relates to the serious sequelae, such as pelvic 
inflammatory disease (PID), infertility, and ectopic pregnancy in women. The nature of the 
infection and the detection of the sequelae much later in life mean that it is difficult to predict the 
number of untreated infections which progress to serious sequelae.  A retrospective study of 
43,715 women in Sweden over a 10-15 year time frame, using health data repositories, indicated 
that for the women who tested positive to C. trachomatis infection; 5.6% had PID, 2.7% had 
ectopic pregnancy, and 6.7% had infertility [4].  A review of published studies by Land and co-
workers found that diagnosed lower genital tract infection can progress to PID in 0.43-31% of 
cases, to tubal infertility in 0.02-4.6% of cases, and PID progresses to tubal infertility in 11.4-
20% of cases [5].  
The pathogenic mechanism, host genetic factors, and other epidemiological factors which lead to 
serious sequelae in a proportion of infected women are not well understood, although it is clear 
that infertility in women is associated with tubal damage resulting in fallopian tube occlusion. 
Additionally, minor tubal adhesions or damage to the cilia lining the fallopian tubes are also 
considered to be C. trachomatis infection related sequelae which impact on fertility. This has 
been further supported by a recent finding by Coppus and co-workers that participants attending 
a fertility clinic with high C. trachomatis serum antibody titers by MIF or ELISA (>1:32 or 1.1 
respectively) with patent tubes by hysterosalpingography (HSG) or laparoscopy, had a 33% 
lower ongoing pregnancy rate [6].  
C. trachomatis antibody titers (CAT) are currently the gold standard for diagnosis of Chlamydia 
related infertility in women. There are two main types of tests which most commonly used; 
immunofluorescence tests (MIF, IF, or WIF) or ELISA. There are several different commercially 
available ELISA tests, and they are typically based on major outer membrane protein (MOMP) 
peptides or LPS. The sensitivity and specificity of these tests varies widely between studies for 
the diagnosis of tubal infertility. A recent meta-analysis by Broeze and colleagues confirmed this 
considerable variation even when the same commercial tests were used between different 
studies. The ELISA (mainly Medac, Biomerieux, Labsystems) sensitivity varied from 12-69%, 
and specificity varied from 62-100% [7]. The immunofluorescence methods were more sensitive 
(50-91%) but had lower specificity (35-85%) [7].  
There are also differences in clinical practice regarding the use CAT as a routine part of 
infertility work up. Many clinics prefer to use HSG or laparoscopy to diagnose tubal infertility in 
women without CAT. The guidelines regarding use of CAT in the preliminary infertility work up 
also vary. The Dutch Society for Obstetrics and Gynecology recommends CAT during initial 
fertility work up and suggest a fixed cut off of IgG MIF 1:32, or ELISA>1.1, as positive cut off 
for CAT[8], whereas CAT is not mentioned in Australian diagnosis recommendations.  More 
accurate CAT implemented during infertility workup has the potential to reduce time to 
successful pregnancy and patient risk by indicating definitive treatment regimes with the goal of 
removing the need for invasive diagnosis by HSG or laparoscopy. 
Despite these differences in clinical acceptance, it remains possible that new assays targeting 
different chlamydial antigens could be used to develop more accurate (sensitive and specific) 
CATs to predict female infertility due to C. trachomatis past infection which could be 
implemented with greater clinical efficacy. This application of a new CAT assay has led to 
proteomic investigations within the field to identify chlamydial antigens for the development of a 
more sensitive and specific CAT to predict Chlamydia-related infertility in women. A genome 
wide study using an expression array identified that a combination of CT443 (OmcB) and CT381 
(ArtJ) had a 67.5% sensitivity and 100% specificity [9]. A proteomic approach searching for B 
and T cell antigens recognized by patients with a high MIF titer frequently identified MOMP, 
HtrA, OmcB, TART, GroEL, LCR-E, and CT662 [10].  In another study using a western blot 
strategy on 2-D gels of the Chlamydia proteome MOMP, PmpD, and OmcB were found to be the 
most specific to infection positive participants (not solely infertility) [11]. HtrA as a full length 
protein was found to be immunoreactive from C. trachomatis infected participants [12].  
In this current study we used a bioinformatics approach to predict single antibody epitopes with 
unique sequence specificity to C. trachomatis from a selected subset of the most frequently 
identified antigens from these previously published proteomic investigations. A library of 
peptides based on these epitopes was used in ELISAs with patient sera to characterize 
performance (sensitivity and odds ratio) with 95% specificity for Chlamydia related sequelae as 
a proof of concept for identifying accurate epitopes for Chlamydia related sequelae. Using this 
approach it is possible that additional antigens be identified that will advance the use of CAT for 
diagnosis of Chlamydia related infertility in women.  
 
 
2. Materials and Methods 
 
2.1 Bioinformatics analysis to predict peptides with C. trachomatis specificity and putative 
B cell antigenicity 
 
C. trachomatis proteins were selected for this study which had previously been identified in 
multiple studies as highly immunoreactive, when screened against serological positive females 
with C. trachomatis infection or C. trachomatis-related tubal factor infertility in more than one 
previous investigations.  These proteins were: HtrA, cHSP60, Ct443, and Ct381 [9-12]. A 
protein unique to Chlamydia pneumoniae (Cpn0236) was also included in the study as a negative 
control [13].  
 
The protein sequences were analysed using a series of in silico bioinformatic analyses to identify 
potential linear B cell epitopes, and the specificity of these epitopes to C. trachomatis. The 
sequences of the proteins of interest were screened for predicted linear B cell epitopes using 
BepiPred algorithm software [14], confirmed with antigenicity prediction software (Kolaskar 
& Tongaonkar Antigenicity) [15], and hydrophilic domains identified to avoid transmembrane 
domains (Parker Hydrophilicity Prediction) [16]. Candidate C. trachomatis HtrA, cHSP60, 
CT443, and CT381 linear B cell epitope peptides were screened for sequence specificity against 
the NR database where BLAST E values were used as criteria; (1) E values < 0.004 for C. 
trachomatis specificity, and (2) E values > 0.1 for C. pneumoniae to remove nonspecific 
epitopes. Regions that did not meet criteria were excluded from further the study. The predicted 
epitopes that met criteria were then used to design a series of 12-mer peptides (Table 1) which 
include partial or complete sequences of these epitopes. Predicted peptide epitopes larger than 12 
amino acids were split into overlapping epitopes. These included epitopes for HtrA (peptides 7-
9; Table 1) and HSP60 (peptides 15-18, 23-28, 32-34, and 37-43; Table 1), two of the most 
highly reported immunogenic antigens for Chlamydia.   
 
2.2 Analysis of Epitope Array to identify epitopes and development of ELISA 
 
The designed peptide epitopes were commercially synthesized using solid phase synthesis onto a 
Biotin-SGSG motif (Mimotopes, Melbourne, Australia). All peptides were solubilized in 50% 
isopropanol overnight on a gentle rocker at room temperature. The initial screening ELISAs were 
conducted using the complete peptide epitope array against 39 participants that sampled all 
cohorts. The ELISAs were conducted using streptavidin coated plates (Reacti-Bind Streptavidin 
High Binding Capacity Coated 96-well Plates, ThermoScientific, Australia) where peptides were 
coated at approximately 0.15 µg per well for one hour at room temperature in PBS/0.1% Tween 
20.  The plates were then washed four times in PBS 0.1% Tween 20, and blocked overnight in 
SuperBlock buffer (Pierce, Australia) with 0.1% Tween 20 at 4°C. The participant sera was 
added to the wells at dilutions of 1/200 and 1/1000 (in Superblock Buffer in PBS with 0.1% 
Tween 20) and incubated for one hour. The plates were washed five times in 2 x PBS with 0.1% 
Tween 20. The secondary antibody used was goat anti-human IgG-HRP (Invitrogen, Australia) 
at a dilution of 1/15000 in SuperBlock Blocking Buffer PBS with 0.1% Tween 20. The plates 
were developed by the addition of 100 µg/ml 3,3,5,5,-Tetramethyl-benzadine (TMB) (Sigma 
Aldrich, Australia) in DMSO dissolved in phosphate citrate buffer with sodium perborate (Sigma 
Aldrich, Australia), incubated for 10 mins at room temperature and stopped by the addition of 
1.0M H2SO4. ELISA plates were read on Bio-Rad xMark Microplate Spectrophotometer at 450 
nm. These ELISAs were conducted by screening the whole array against each participant sera 
with primary and secondary antibody only controls on each plate. The peptides that fit criteria for  
further development in the initial analysis were then subjected to further analysis. Optimized 
assays were attempted, which included further serological dilution series, and a variety of 
alteration in washing conditions. The optimized peptide 11 ELISA was conducted as per the 
above protocol except that 0.2 µg of peptide was coated to each well. 
 
2.3 Participant/Cohort collection and definitions 
 
Participants (female) were recruited as a part of the Queensland Chlamydia Research Network 
which includes all Queensland Health Sexual Health Clinics, QUT Health Services Medical 
Centre, and The Wesley Reproductive Medicine and Gynecological surgery unit. The 
participants were fully informed and consented prior to participation in the study. Ethical 
approval for the study was obtained via the following Human Research Ethics Committees: QUT 
Human Research Ethics Committee approval number 080000268, Prince Charles Hospital 
Human Research Ethics Committee approval number EC2809, Ipswich and West Moreton 
Health Services District Human Research Ethics committee approval number (10-09), Gold 
Coast Hospital District Human Research Ethics Committee approval number (200893), Cairns 
Sexual Health Clinic (HREC/09/QCH/4-554), and The Wesley Hospital Human Research Ethics 
Committee (2008/02). Clinical data was collected from all participants including: age, number of 
sexual partners, fertility status (if known), self reported and patient chart reported history of 
sexually transmitted infections, current and previous C. trachomatis infections, contraceptive use 
and type. Participants sourced from the Wesley Reproductive Medicine and Gynecological 
surgery unit were also asked to allow their gynecologist to provide additional data relating to 
their infertility status and infertility cause. Participants from this clinic were all tested for C. 
trachomatis infection history using both the MEDAC and Bioclone C. trachomatis ELISAs 
(sourced from Bioclone, Sydney, Australia and MEDAC sourced from Biocene, Sydney 
Australia). Potentially confounding participants were excluded where they were found to be both 
seropositive to C. trachomatis and had a diagnosed cause of infertility that was not tubal factor.  
These participants were excluded due to the potential for their infertility to still relate to C. 
trachomatis immunopathology.  
 
Participants (female) recruited from the Queensland Chlamydia Research Network were divided 
into four C. trachomatis cohorts; sequelae, acute, multiple and infertility controls (subdivided by 
C. pneumoniae serological status). The sequelae cohort included women who had a history of 
PID, tubal ectopic pregnancy, or tubal factor infertility (laparoscopy diagnosis) and also a history 
of C. trachomatis infection (either by recorded participant medical chart recorded PCR positive 
previous infection, or C. trachomatis positive serology by MEDAC and Bioclone assays).  Acute 
participants were those who had a history of single treated C. trachomatis infection (PCR 
diagnosis) with no reported sequelae, and the multiple infections cohort included participants 
who had a history of more than one treated C. trachomatis infection (PCR diagnosis) with no 
reported sequelae. These two cohorts were generally recruited at the Sexual Health Clinics.  The 
infertility control cohort included women attending the IVF clinic who were infertile but did not 
have tubal factor infertility; these participants were all negative for C. trachomatis serology by 
the MEDAC and Bioclone tests.    
 
Participants (female) were also recruited from patients attending the Gynecology outpatient 
department at the Sarfdarjung Hospital, New Delhi, India. Participants were informed and 
consented to participate in the study. The study was approved by the Sarfdarjung Hospital 
Human Research Ethics Committee. Clinical data collected included; age, regularity of 
menstrual cycle, years of infertility (if infertile), clinical details such as cervicitis, bacterial 
vaginosis, Mycoplasma sp. culture, Ureaplasma sp. by culture, bacterial vaginosis, and C. 
trachomatis infection status by direct fluorescence assay and PCR from swabs.  Participants from 
this study were divided into cohorts based on infertility (primary or secondary; any cause), 
cervicitis and current C. trachomatis genital infection status (assayed by PCR and DFA). 
 
 
3. Results 
 
3.1 Screening new peptide antigens using ELISA confirms bioinformatic predictions and 
identifies potential new antigens for Chlamydia antibody testing 
 
The peptide array (55 unique peptides) was developed using a series of bioinformatic analyses of 
the most commonly reported proteins to have a serological response in C. trachomatis 
participants. Proteins previously frequently identified during screening or proteomic studies 
when screening with participant sera from C. trachomatis positive participants were selected 
(HtrA, Hsp60, CT443, and CT381), along with a C. pneumoniae specific protein as a negative 
control (CP0236). MOMP was not included for this study given the existing peptide ELISAs 
based on this protein and the serovar specific sequence variability in this protein. These proteins 
were then searched bioinformatically for B cell epitopes, as outlined in the Materials and 
Methods. Predicted epitopes were then searched by BLAST to reduce the pool of potential 
epitopes to only those which had high sequence specificity to C. trachomatis.  An initial 
screening assay was conducted to identify peptides which may be useful detectors of the 
sequelae disease cohort. The peptide array was screened in duplicate against 39 participant sera 
belonging to the four cohorts; sequelae, acute, multiple, and infertility controls (subdivided by C. 
pneumoniae serological status). The raw values for each epitope from each participant in each 
cohort were then analyzed (Table 1). The data was analyzed by ANOVA, comparing the data for 
each cohort to either sequelae or infertility control groups.  Only peptide 47 showed a significant 
difference (p<0.05, sequelae c.f. acute) when the results were tested for statistical significance 
between the cohorts during this initial screening ELISA. Specific criteria for sequelae specificity 
was then applied to select peptide epitopes for further analysis. 
 
In order to identify which peptides have the potential for further assay optimization for specific 
detection of the sequelae cohort a set of criteria were used to select the peptides to develop 
further. The three criteria were: 1. achieve a higher average absorbance in the sequelae cohort 
compared to the combined infertility controls (a difference off of >0.015 was chosen), 2. to avoid 
false positive detection due to prior C. pneumoniae infection (<0.015 difference between the C. 
pneumoniae subdivided infertility controls), and 3. distinguish sequelae from acute participants 
(>0.015 different in absorbance between the two cohorts) (Table 1). These three criteria 
identified the following four peptides (protein source of the peptide is indicated); 11 (HtrA: 
MGVRVQNITGLA), 48 (HSP60: SLSSSPEHSQEE), 51 (Ct443: LTVPVSDTENTH), and 52 
(Ct381: VGIGVASDRPAL).  
 
 3.2 Peptide 11 ELISA is an effective serological diagnostic for chlamydial tubal factor 
infertility 
In order to optimize the serological assay, performance of the different assay conditions trialed 
with the different sera dilutions for each of the four peptides were assessed by area under the 
curve analysis.  Specificity was controlled at ≥95% to establish absorbance (450nm) thresholds 
reflecting a diagnostic use to detect those women who have C. trachomatis sequelae from C. 
trachomatis infection or negative cohorts. Peptide 11 showed the most rigorous performance and 
hence only the data from this peptide is shown here. Figure 1 shows the receiver operator 
characteristic curve for the sera at a 1/200 dilution comparing participants from sequelae and 
infertility control cohorts.  The tested dilution series did not significantly change the accuracy of 
the test as there was negligible difference in area under the curve. The selection of 1/200 dilution 
was one of practicability, as the absorbance threshold was to be 0.184 at a 1/800 dilution and 
0.296 at a 1/200 dilution which achieves a better signal to noise threshold for assay development. 
The 1/200 dilution peptide 11 assay with a 0.296 absorbance threshold was found to be able to 
statistically discriminate participants in the sequelae cohort from infertility controls and from 
acute cohorts (Table 2).  The comparison of sequelae to infertility controls yielded an odds ratio 
of 16.3 with a 95% confidence interval 1.63-160 (P = 0.005). The bioinformatic prediction that 
the test will not be influenced by C. pneumoniae serological status was also supported by its 
performance against the infertilty controls, which includes 7 C. pneumoniae seropositive 
participants. The test was also able to produce a positive odds ratio (5.14; 95% confidence 
interval 1.12-23.5) for sequelae compared to the acute infection cohort, as per the third design 
criteria. The optimised peptide 11 assay was not able to statistically discriminate sequelae from 
the multiple infection cohort at the 0.296 absorbance threshold (P = 0.091), but did yield a 
positive odds ratio (4; 95% confidence interval 0.763 – 21.0) for the comparison. These results 
are supportive of the potential utility of such a test during the initial infertility investigation 
where women with sequelae are clearly distinguished from women with a previous acute 
infection or women who are negative.  
In order to further analyse if it might be possible to develop a test to distinguish between women 
potentially at risk of developing sequelae (such as women with multiple exposures) from women 
who have had an infection with no evidence of sequelae a different analysis was conducted using 
a different absorbance cut off. The specificity for detecting multiple infections and sequelae from 
acute could be further improved by increasing the absorbance threshold to 0.408, but resulted in 
a decrease of statistical significance from the 0.296 absorbance threshold for the sequelae vs 
acute comparison  (P(Abs=0.296) = 0.012 to P(Abs=0.08) = 0.050; Table 2). Whilst these 
analyses were not statistically significant it indicates that this an approach were the assay may 
have utility at the GP clinic for women who wish to determine their future infertility risk could 
be developed from this peptide-epitope strategy.  
 
3.3 Testing the peptide 11 assay as a serological diagnostic using cohort of women attending 
a gynecology clinic in India  
 
The Peptide 11 ELISA was then tested against participants recruited by the Sarfdarjung Hospital 
Gynaecology Clinic, South Delhi. The peptide 11 ELISA was tested on 129 participant's sera 
attending the clinic using the optimized 1/200 dilution of sera with the designed 95% specificity 
absorbance threshold of 0.296.  Nine women tested positive to the peptide 11 ELISA (Table 3) 
which included 7 women with cervicitis and primary infertility and 2 women with primary 
infertility and current C. trachomatis infection.  These proportions were significantly different to  
those who tested negative (P=0.039).  The women who tested positive in the peptide 11 ELISA 
compared to those who tested negative were analyzed for any potential confounders which may 
have influenced the result. There was no statistical significance in age of women who tested 
positive and those who tested negative (p=0.3458, 28.43 average years for peptide 11 positive 
c.f. 30.16 average years for peptide 11 negative), or in the patient reported years of infertility 
(p=0.6802, 6.47 compared to 7.11 years for peptide 11 positive group). Furthermore, there were 
no significant differences in those women who were positive in the peptide 11 ELISA and 
whether or not they had current genital infections (Mycoplasma, or Ureaplasma). In comparison, 
the MEDAC MOMP ELISA detected 5 women (absorbance above 1.1) including; 2 women with 
C. trachomatis and cervicitis, 2 women with primary infertility, and 1 primary infertility with C. 
trachomatis infection, who was also detected by the peptide 11 assay. These proportions were 
not significantly different from those who were negative to the MEDAC MOMP ELISA 
(P=0.529). 
 
All of the women who were peptide 11 positive were women with primary infertility (Table 3).  
Those women who were positive in the peptide 11 ELISA had an odds ratio of 8.8 (95% 
confidence interval 0.5-156.29) of having primary infertility and not cervicitis or secondary 
infertility (irrespective of C. trachomatis status), but the comparison was not statistically 
significant (P = 0.075). A positive MEDAC MOMP ELISA result had a lower odds ratio of 1.82 
(95% confidence interval 0.29-11.28) for the same comparison and was also not statistically 
significant (P=0.240).  Raw absorbance values for the peptide 11 ELISA did not correlate with 
MEDAC MOMP ELISA (R2 = 0.001, P = 0.677) supporting the independence of these tests and 
differing rates of detection.  Whilst a large number of the women recruited at this clinic were 
positive for a current C. trachomatis infection (47 positive by both urine DFA and PCR), 2 of the 
9 women who tested positive using the peptide 11 test also had a current infection further 
supporting that the design of the test does not bias towards detection women with acute 
infections in the context of other pathology.  Sensitivity and specificity of peptide 11 or MEDAC 
performance relative to the gold standard of laparoscopy or HSG was not possible on these 
patients.  
 
4. Discussion 
This paper reports for the first time that a peptide epitope from C. trachomatis HtrA has the 
potential to be further developed into a specific diagnostic to detect serious sequelae from this 
infection. Women who reacted positively in the peptide 11 ELISA developed during this study 
had a 16.3 odds ratio of having C. trachomatis sequelae (tubal infertility, ectopic pregnancy, or 
PID) (specificity 95% and sensitivity 46%). The test also showed the potential to distinguish 
these women with sequelae from women with a history of C. trachomatis single treated infection 
(P=0.027, Table 2) or multiple infections (P=0.091, Table 2), although the cohort numbers were 
not large enough in this study to provide statistical validity. This is an important finding as very 
few studies reporting new antigens for diagnosis of tubal factor infertility report the performance 
of the test against infection cohorts (such as acute or multiple infections). Certainly cohort 
definitions in studies such as these are difficult, as patients may have had previous untreated 
infections. However, given that some of the acute and multiple infection participants included in 
this study have been sourced at sexual health clinics it is likely that this cohort includes a some 
participants who may have more infections than diagnosed and yet the assay was still specific to 
the sequelae cohort (Table 2). The poor sensitivity observed in this study may be improved by 
future optimization of peptide concentrations or multiple peptide combination assay formats. 
Whilst the sensitivity and technical parameters (absorbance, signal to noise ratio) of the assay are 
clearly not adequate for implementation as a diagnostic in it’s current format, these results 
support that using bioinformatics can help to eliminate issues with specificity (i.e. cross 
reactivity due to C. pneumonia sero-positive status), which has been a perceived barrier to 
implementation of CAT.  This study has been limited to proteins previously identified as highly 
immunoreactive for Chlamydia thus, it provides proof of concept that this strategy, along with 
further assay development (such as assessing assay performance against standard serological 
tests and improved technical parameters), could be successfully implemented to identify new 
specific antigens for CAT diagnosis of Chlamydia tubal factor infertility. The potential 
application of this assay during the initial infertility investigation is clearly the major focus, 
hence the need for high specificity so that few false positives are diagnosed even though with the 
current low sensitivity some true positives will not be diagnosed. However, the analysis using a 
different absorbance cut off to distinguish between the acute and multiple and acute and sequelae 
cohorts also supports that with further technical development an assay of this format may also 
have utility at the GP clinic where women may be seeking to examine their fertility risks. 
Therefore, the overall strategy of using a combination of previous proteomic data on 
immunogenic antigens and bioinformatic tools to select epitopes for peptide ELISA data was 
supported by the findings in this study. 
The peptide 11 ELISA in the current format was tested in another setting and it was found that 9 
out of 129 women attending a gynecology clinic in India would be predicted to have tubal 
infertility using this assay. Interestingly, all of these women had primary infertility and none of 
the women with secondary infertility were positive by this assay (no significant age difference). 
The results of the peptide 11 ELISA and MEDAC MOMP assays were different, however, whilst 
MEDAC MOMP titre above 1.1 is recommended in the Dutch fertility guidelines as a diagnostic 
for C. trachomatis sequelae this assay is actually marketed by the manufacturer as test for 
infection history. Hence, the different performance of these two assays is not necessarily 
unexpected. There were 47 women with a current C. trachomatis infection of the 129 women 
recruited for this study (36.4%). This prevalence is slightly higher than a previously reported 
prevalence of C. trachomatis positive women at another clinic in Delhi, however there is 
potential for a recruitment bias in our study as the clinicians were aware that this is a Chlamydia 
research study (24-30%) (PCR diagnosis) [17]. C. trachomatis infection prevalence in 
populations in India (generally sexual health clinic, gynecology clinic or sex worker screening 
studies) varies from 7%-30% [18-19]. It is more difficult to estimate the likely percent of 
infertility that relates to Chlamydia-mediated tubal factor infertility. However, we can be guided 
by two different prospective studies where women attending IVF clinics were recruited, and the 
percent of participants with tubal infertility and a positive antibody testing for a history of 
Chlamydia infection calculated to be the prevalence of Chlamydia related tubal infertility. In a 
study based in Denmark this prospective screening approach identified that that 6.9% of infertile 
women attending the IVF clinic was due to C. trachomatis tubal infertility [20]. For a similar 
study conducted in China 7.6% of women attending the IVF clinic had C. trachomatis tubal 
infertility [21]. The participants attending the clinic in India for this current investigation do not 
have access to laparoscopy or HSG technologies, meaning it is not possible to validate the results 
of the peptide 11 assay in this second cohort. However, 7.0% of the participants attending the 
clinic, all with primary infertility, were positive by this assay. 
Overall, this study has provided proof of concept that new peptide based ELISAs which are 
highly specific for detection of women with C. trachomatis sequelae such as tubal factor 
infertility can be developed. The assay is under further development to improve the sensitivity by 
including multiple markers within the assay which has shown increased sensitivity [9]. Increased 
sensitivity may make this assay a useful diagnostic for initial fertility work up, and these 
potential improvements may also be useful for implementation as a screening tool in 
epidemiological studies, or within general practice as an early warning system for women to plan 
their families..  
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 Figure legends 
Figure 1: Receiver operator characteristic curve for the sera dilution of 1/200 comparing 
participants from sequelae and infertility control cohorts. In the box (bottom left) area under 
the curve (AUC) for 1/200, 1/400 and 1/800 sera dilutions are shown with calculated absorbance 
(450nm) thresholds for a 95% specificity cutoff. Dashed line indicates the 95% specificity (x-
axis) cutoff which corresponds to 46% sensitivity (y-axis). 
 
 
 
